Product group In-vitro diagnostics - equipment / products for clinical chemistry
Reference 49951/25

Product group Physical therapy - insufflation technique
Reference 21354/25

Product group Medical data processing (software) - software for computer-based treatment
Reference 28334/25

Updated information Iris Webinar - January 2026

Active substance: thalidomide, lenalidomide, pomalidomide The Federal Institute for Drugs and Medical Devices (BfArM) once again draws attention to the applicable safety regulations and the requirements for the proper prescription of thalidomide, lenalidomide and pomalidomide.

Successful Regional Training on Bioequivalence Study Assessment Held in Nairobi

Aerosol dispensers containing fluorinated greenhouse gases, including medicinal metered dose inhalers, may only be placed on the market, supplied or made available to third parties in the EU from 1 January 2025 if they are labelled in accordance with Article 12(3) of Regulation (EU) 2024/573 on fluorinated greenhouse gases (F-Gas Regulation).

Structure of the BfArM (date 08.12.2025)

Structure of the BfArM (date 08.12.2025)

The following table gives an overview of the herbal, homeopathic and anthroposophic medicinal products with completed marketing authorisation or registration procedure which are available on the German market.

spec-ICD11-V2025S10 PDF

spec-ICD11-V2025S10

Active substance: sodium oxybate The European Medicines Agency (EMA) is starting to review medicines containing sodium oxybate.

The next Iris webinar will be held on 9^th July 2025.

Role Identification of Causes of Death Algorithm (RICoDA version 2_1)

Request for super-grouping

Reporting Recalls

Release notes Iris MUSE V6.1.0.9

Below you will find all important information about the changes in the radiation protection act applicable since 01.07.2025.

For studies with submission in CTIS and DMIDS, only one radiation protection submission is required - depending on the study focus CTIS or DMIDS.